A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
Clinical trial NCT05228496 · UNKNOWN
Trial details
- NCT number
- NCT05228496
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-17
- Primary completion
- 2023-07-21
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.